IL6R and COVID-19: Currently, some clinical trials have shown beneficial effects of some approved drugs on COVID-19, including IL6R antagonist3 ACE inhibitor,4 Peginterferon Lambda-1a,5 fluvoxamine,6 Calcium release-activated calcium (CRAC) channel inhibitors,7 Janus kinase 1/2 inhibitor,8 vitamin D.9In parallel, some experimental studies have identified a set of human proteins that interact with SARS-CoV-2,10 and may provide drug targets for general coronavirus interventions.